Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters
BUT TOTALLY WORTH IT
Ashram Road, Ahmedabad - 380009, Gujarat, India Country of origin: INDIA Expiry on or after: November 2026 In case of any issues, contact us: [email protected]|09240250346 Address: 6th floor, Urmi Corporate Park Solaris, Saki Vihar Road, Andheri East, Mumbai 400071 References Vitamin B12: Uses, interactions, mechanism of action | DrugBank Online
The MHRA recommends considering periodic B12 monitoring in patients on metformin who have risk factors for deficiency, and testing if symptoms develop
This result is consistent with previous investigations of the interaction between FOXO4 FHD and p53 TAD using chemical shift perturbation (CSP) 38
